Targeted Lipid Particles For Systemic Delivery Of Nucleic Acid Molecules To Leukocytes
Patent No. EP3303598 (titled "Targeted Lipid Particles For Systemic Delivery Of Nucleic Acid Molecules To Leukocytes") was filed by Ramot AT TEL Aviv University on May 25, 2016. The application was issued on Mar 19, 2025.
Patent Summary
Targeted lipid-based particles for efficient and specific delivery of nucleic acid molecules to leukocytes, particularly T cells and B cells. The particles contain a lipid mixture with cationic lipid, membrane stabilizing lipid, and PEG-maleimide conjugated to a targeting moiety. They encapsulate siRNA molecules specifically targeting CD38 or CD38-related molecules on B cells, enabling targeted gene silencing in B-cell malignancies like MCL.
Patent Family
Patent Oppositions (3)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3303598
- Application Number
- EP16799476A
- Filing Date
- May 25, 2016
- Status
- Granted And Under Opposition
- Feb 14, 2025
- Publication Date
- Mar 19, 2025
- External Links
- Slate, Register , Google Patents